MedTrace Logo

COMPARISON OF ERECTOR SPINA PLAN BLOCK AND THORACIC PARAVERTEBRAL BLOCK FOR PERIOPERATIVE ANALGESIA

NCT07021651 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-06-15

No results posted yet for this study

Summary

The primary aim of this study was to compare the postoperative analgesic efficacy of thoracic paravertebral block with erector spinae plane block, which we use in thoracotomy surgeries. Secondary aims were to compare these groups in terms of Riker Agitation-Sedation Scale (RASS) scores, postoperative complications, postoperative opioid consumption, and patient satisfaction.

Conditions

  • Paravertebral Block

Interventions

PROCEDURE

Erector Spinae Plane (ESP) block admistring

In the ESPB group, the probe was placed longitudinally at the level of the T5 transverse process, 2-3 cm lateral from the midline. The muscles were visualized superior to the transverse process ; then, the needle was inserted in the craniocaudal direction using the in-plane technique. A dose of 2 mL normal saline were injected into the two layers of the interfacial area under the erector spinae muscle, and the proper injection site was confirmed. After visualizing the linear spread of saline in the fascial plane, 20 mL of 0.25% bupivacaine was injected there for the block.

PROCEDURE

Thoracic Paravertebral Block administring

In the TPVB group, the probe was placed 2-3 cm laterally and vertically of the T5 spinous process. Once the transverse process, corresponding paravertebral space, internal intercostal membrane, and pleura was identified , the needle was inserted in the lateromedial direction using the in-plane technique. After confirmation of pleural displacement with 2 mL saline, 20 mL of 0.25% bupivacaine was administered for the block.

Sponsors & Collaborators

  • Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-07-10
Primary Completion
2025-07-20
Completion
2025-08-01

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07021651 on ClinicalTrials.gov